These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 39001729)

  • 21. Quantitative Late Gadolinium Enhancement Cardiac Magnetic Resonance and Sudden Death in Hypertrophic Cardiomyopathy: A Meta-Analysis.
    Kiaos A; Daskalopoulos GN; Kamperidis V; Ziakas A; Efthimiadis G; Karamitsos TD
    JACC Cardiovasc Imaging; 2024 May; 17(5):489-497. PubMed ID: 37632503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High T2-weighted signal intensity for risk prediction of sudden cardiac death in hypertrophic cardiomyopathy.
    Gommans DHF; Cramer GE; Bakker J; Dieker HJ; Michels M; Fouraux MA; Marcelis CLM; Verheugt FWA; Timmermans J; Brouwer MA; Kofflard MJM
    Int J Cardiovasc Imaging; 2018 Jan; 34(1):113-120. PubMed ID: 29063221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Entropy of left ventricular late gadolinium enhancement and its prognostic value in hypertrophic cardiomyopathy a new CMR assessment method.
    Zhao X; Jin F; Wang J; Zhao X; Wang L; Wei H
    Int J Cardiol; 2023 Feb; 373():134-141. PubMed ID: 36395920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function.
    Mentias A; Raeisi-Giglou P; Smedira NG; Feng K; Sato K; Wazni O; Kanj M; Flamm SD; Thamilarasan M; Popovic ZB; Lever HM; Desai MY
    J Am Coll Cardiol; 2018 Aug; 72(8):857-870. PubMed ID: 30115224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Role of the Progression of Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy.
    Aquaro GD; Todiere G; Barison A; Grigoratos C; Parisella ML; Adami M; Grilli G; Pagura L; Faggioni L; Cioni D; Lencioni R; Emdin M; Neri E
    Am J Cardiol; 2024 Jan; 211():199-208. PubMed ID: 37949342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction.
    Funada A; Kanzaki H; Noguchi T; Morita Y; Sugano Y; Ohara T; Hasegawa T; Hashimura H; Ishibashi-Ueda H; Kitakaze M; Yasuda S; Ogawa H; Anzai T
    Heart Vessels; 2016 May; 31(5):758-70. PubMed ID: 25820658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The value of cardiac MRI in the risk stratification in patients with hypertrophic cardiomyopathy].
    Wang JX; Yang SJ; Ma X; Yu SQ; Dong ZX; Xiang XR; Wei ZX; Cui C; Yang K; Chen XY; Lu MJ; Zhao SH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2023 Jun; 51(6):619-625. PubMed ID: 37312480
    [No Abstract]   [Full Text] [Related]  

  • 28. Prognostic value of left atrial function by cardiovascular magnetic resonance feature tracking in hypertrophic cardiomyopathy.
    Hinojar R; Zamorano JL; Fernández-Méndez M; Esteban A; Plaza-Martin M; González-Gómez A; Carbonell A; Rincón LM; Nácher JJJ; Fernández-Golfín C
    Int J Cardiovasc Imaging; 2019 Jun; 35(6):1055-1065. PubMed ID: 30706353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation.
    Papavassiliu T; Germans T; Flüchter S; Doesch C; Suriyakamar A; Haghi D; Süselbeck T; Wolpert C; Dinter D; Schoenberg SO; van Rossum AC; Borggrefe M
    J Cardiovasc Magn Reson; 2009 Sep; 11(1):34. PubMed ID: 19740409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy.
    Ismail TF; Jabbour A; Gulati A; Mallorie A; Raza S; Cowling TE; Das B; Khwaja J; Alpendurada FD; Wage R; Roughton M; McKenna WJ; Moon JC; Varnava A; Shakespeare C; Cowie MR; Cook SA; Elliott P; O'Hanlon R; Pennell DJ; Prasad SK
    Heart; 2014 Dec; 100(23):1851-8. PubMed ID: 24966307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modes of death and clinical outcomes in adult patients with hypertrophic cardiomyopathy in Thailand.
    Songsirisuk N; Kittipibul V; Methachittiphan N; Charoenattasil V; Zungsontiporn N; Spanuchart I; Buppajarntham S; Mankongpaisarnrung C; Satitthummanid S; Srimahachota S; Chattranukulchai P; Boonyaratavej Songmuang S; Puwanant S
    BMC Cardiovasc Disord; 2019 Jan; 19(1):1. PubMed ID: 30606129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of left atrial strain analysis in adverse clinical events in patients with hypertrophic cardiomyopathy: a CMR study.
    Tian D; Zhang J; He Y; Xiong Z; Zhao M; Hu S; Song Q; Li Z
    BMC Cardiovasc Disord; 2023 Jan; 23(1):42. PubMed ID: 36690952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late gadolinium enhancement is common in patients with hypertrophic cardiomyopathy and no clinical risk factors for sudden cardiac death: A single center experience.
    Lyons KS; Dixon LJ; Johnston N; Noad R; Hamilton A; McKeag N; Horan P
    Cardiol J; 2014; 21(1):29-32. PubMed ID: 23990187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.
    Bogarapu S; Puchalski MD; Everitt MD; Williams RV; Weng HY; Menon SC
    Pediatr Cardiol; 2016 Apr; 37(4):663-73. PubMed ID: 26833321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic implications of global myocardial mechanics in hypertrophic cardiomyopathy by cardiovascular magnetic resonance feature tracking. Relations to left ventricular hypertrophy and fibrosis.
    Hinojar R; Fernández-Golfín C; González-Gómez A; Rincón LM; Plaza-Martin M; Casas E; García-Martín A; Fernandez-Mendez MA; Esteban A; Nacher JJJ; Zamorano JL
    Int J Cardiol; 2017 Dec; 249():467-472. PubMed ID: 29121751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.
    Avanesov M; Münch J; Weinrich J; Well L; Säring D; Stehning C; Tahir E; Bohnen S; Radunski UK; Muellerleile K; Adam G; Patten M; Lund G
    Eur Radiol; 2017 Dec; 27(12):5136-5145. PubMed ID: 28616729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients.
    Hu DJ; Xu J; Du W; Zhang JX; Zhong M; Zhou YN
    Int J Cardiovasc Imaging; 2016 Dec; 32(12):1725-1733. PubMed ID: 27566192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR.
    Moravsky G; Ofek E; Rakowski H; Butany J; Williams L; Ralph-Edwards A; Wintersperger BJ; Crean A
    JACC Cardiovasc Imaging; 2013 May; 6(5):587-96. PubMed ID: 23582356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incremental benefit of late gadolinium cardiac magnetic resonance imaging for risk stratification in patients with hypertrophic cardiomyopathy.
    Doesch C; Tülümen E; Akin I; Rudic B; Kuschyk J; El-Battrawy I; Becher T; Budjan J; Smakic A; Schoenberg SO; Borggrefe M; Papavassiliu T
    Sci Rep; 2017 Jul; 7(1):6336. PubMed ID: 28740148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early gadolinium enhancement in hypertrophic cardiomyopathy: a potential premature marker of myocardial damage.
    Pozo E; Viliani D; Aguirre N; Agudo-Quilez P; Olivera MJ; Caballero P; Jiménez-Borreguero LJ; Alfonso F
    Int J Cardiovasc Imaging; 2016 Nov; 32(11):1635-1643. PubMed ID: 27503551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.